- Home
- AZ vs ALEC Comparison
AZ vs ALEC Comparison
Compare AZ & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | ALEC |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 275.8M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AZ | ALEC |
|---|---|---|
| Price | $5.70 | $1.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $22.50 | $3.90 |
| AVG Volume (30 Days) | 398.3K | ★ 3.8M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $350.76 | $214.33 |
| Revenue Next Year | $206.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.97 | $1.09 |
| 52 Week High | $8.73 | $3.34 |
Technical Indicators
Market Signals| Indicator | AZ | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 47.11 |
| Support Level | $5.16 | $1.89 |
| Resistance Level | $6.27 | $2.17 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 33.11 | 18.50 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.